It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common enzymopathy in humans, affecting ~ 500 million worldwide. A detailed study of the structural stability and catalytic activity of G6PD variants is required to understand how different mutations cause varying degrees of enzyme deficiency, reflecting the response of G6PD variants to oxidative stress. Furthermore, for G6PD double variants, investigating how two mutations jointly cause severe enzyme deficiency is important. Here, we characterized the functional and structural properties of nine G6PD variants: G6PD Gaohe, G6PD Mahidol, G6PD Shoklo, G6PD Canton, G6PD Kaiping, G6PD Gaohe + Kaiping, G6PD Mahidol + Canton, G6PD Mahidol + Kaiping and G6PD Canton + Kaiping. All variants were less catalytically active and structurally stable than the wild type enzyme, with G6PD double mutations having a greater impact than single mutations. G6PD Shoklo and G6PD Canton + Kaiping were the least catalytically active single and double variants, respectively. The combined effects of two mutations were observed, with the Canton mutation reducing structural stability and the Kaiping mutation increasing it in the double mutations. Severe enzyme deficiency in the double mutants was mainly determined by the trade-off between protein stability and catalytic activity. Additionally, it was demonstrated that AG1, a G6PD activator, only marginally increased G6PD enzymatic activity and stability.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Mahidol University, Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine, Bangkok, Thailand (GRID:grid.10223.32) (ISNI:0000 0004 1937 0490)
2 King Mongkut’s Institute of Technology Ladkrabang, Department of Chemical Engineering, School of Engineering, Bangkok, Thailand (GRID:grid.419784.7) (ISNI:0000 0001 0816 7508)
3 Chulabhorn Royal Academy, Princess Srisavangavadhana College of Medicine, Bangkok, Thailand (GRID:grid.419784.7)
4 Mahidol University, Department of Biochemistry, Faculty of Science, Bangkok, Thailand (GRID:grid.10223.32) (ISNI:0000 0004 1937 0490); Mahidol University, Center for Excellence in Protein and Enzyme Technology, Faculty of Science, Bangkok, Thailand (GRID:grid.10223.32) (ISNI:0000 0004 1937 0490)
5 National Science and Technology Development Agency, National Center for Genetic Engineering and Biotechnology, Pathum Thani, Thailand (GRID:grid.425537.2) (ISNI:0000 0001 2191 4408)




